Jason Huo, PhD

Somnolence and Sedation with Lumateperone Treatment: A Comparison of Morning and Evening Administration

Background: Somnolence and sedation are common treatment-emergent adverse events (TEAEs) reported with current antipsychotics. Lumateperone (lumateperone tosylate, ITI-007), a mechanistic...

Sharon Mates , PhD;

Andrew J. Cutler , MD;

William Rowe , MSN, RN, ACNP, BC;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Jason Huo , PhD;

10/08/2020

Efficacy and Safety of Lumateperone (ITI-007) in the Treatment of Depressive Episodes Associated With Bipolar I and II Disorders

Background: Treatments for bipolar depression are limited. Lumateperone (lumateperone tosylate, ITI-007), a mechanistically novel antipsychotic that simultaneously modulates serotonin, do...

Joseph Calabrese , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Jason Huo , PhD;

Sharon Mates , PhD;

Ian D'Souza , PhD;

Susan Kozauer , MD;

10/08/2020

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

April 30 ⁠–⁠ May 5

WoundCon

May 1 ⁠–⁠ May 3

May 19 ⁠–⁠ May 21

See Full Calendar